SCOTTISH entrepreneur Speaking after the unveiling yesterday of an investment in Aridhia by
It is understood that
He also highlighted NHS Scotland's use of Aridhia's platform to analyse data relating to patients who are on complex mixes of medication for multiple chronic conditions. He said that such data analysis could ensure patients at risk of medication complications were flagged up.
Aridhia has positioned itself to support the effective management of chronic diseases today, and a shift in future to "stratified" and "personalised" medicine, where a patient's molecular profile is used to tailor preventative measures or treatments based on the likelihood of response.
He said this was not how health services are currently delivered. However, he highlighted an "incredibly widespread view" that this was how health services would be delivered over the next five, 10 or 15 years.
Aridhia, which does not disclose revenue figures, has 82 people working for it, including clinicians, life scientists, computer scientists, and data scientists.
Referring to the funding injection from Albion and SEP, he said: "It is a big investment."
Emphasising that the venture capitalists had no plans to make an exit from the company or float it on the stock market in the short term,
He added: "Healthcare is an industry where costs have risen more than GDP [gross domestic product] for the last 40 years, worldwide. It is the one industry where, it is fair to say, the impact of informatics, analytics, big data, has had the smallest impact."
Aridhia's client base also includes the
He added: "We are taking a pretty sizeable investment, which is really driven around a go-to-market model, nationally and internationally, with the products we have developed over the past five years. We have got a real path to pretty substantial growth."
Speaking after the unveiling yesterday of an investment in Aridhia by